BridgeBio Pharma to Participate in September Investor Events
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, has announced its participation in three major investor conferences in September 2024: 1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, has announced its participation in three major investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Health Care Conference in New York, NY on September 4th at 10:00 am ET (Fireside Conversation)
2. Wells Fargo 19th Annual Healthcare Conference 2024 in Boston, MA on September 5th
3. Cantor Global Healthcare Conference in New York, NY on September 17th at 10:20 am ET (Presentation)
Investors can access live webcasts of BridgeBio's presentations on the company's website. Replay of the webcasts will be available for 90 days following each event.
Details
News Market Reaction – BBIO
The recorded move for BBIO in the trading session of this news was -0.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Health Care Conference, New York, NY: Fireside Conversation on September 4th at 10:00 am ET
- Wells Fargo 19th Annual Healthcare Conference 2024, Boston, MA, September 5th
- Cantor Global Healthcare Conference, New York, NY: Presentation on September 17th at 10:20 am ET
To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.